DKA Side Effect Linked To Drug Use By Invokana Lawsuit Plaintiffs And FDA Reports

May 16, 2016 – – TheProductLawyers.com comments on reports issued by the Institute for Safe Medication Practices (ISMP) and the U.S. Food and Drug Administration (FDA) related to Invokana and potentially life-threatening side effects being reported by diabetic patients taking the drug, as well as the other sodium-glucose cotransporter-2 (SGLT2) inhibitor drugs for the treatment of their type 2 diabetes.

The ISMP in its May 2015 QuarterWatch Report signaled concern about Invokana and its linkage to more than 457 adverse events that were considered serious or severe within the first year the drug was released on the market. Of these reports, 54 focused on kidney failure and renal impairment. Kidney failure ensues when the organs no longer do the work they need to do of removing toxins from the body.

Invokana is intended to treat those individuals with type-2 diabetes and help them maintain proper blood sugar levels by preventing the kidneys from absorbing excess sugar back into the body. Invokana facilitates the removal of the excess sugar via urination instead, thus placing a heavier burden on the kidneys and making them much more susceptible to possible damage. Once the kidneys are damaged it is an irreparable situation and can ultimately cause kidney failure, the need for dialysis and a kidney transplant.

The FDA in December of 2015 issued a public safety communication linking Invokana in numerous adverse event reports to severe kidney risks, especially in those patients with pre-existing kidney issues. In more than 50 reports, the focus was on renal impairment and kidney failure in patients taking the drug within the first year alone that the drug was released on the market.

Additionally discussed in the FDA report were new warning label requirements mandated by the agency, specifically addressing the potential risks related to the onset of diabetic ketoacidosis as well as urinary tract infections (UTI’s) that turned into more severe blood and kidney infections, as stated in 19 adverse event documents submitted to the agency.

For more information about the Invokana lawsuits, or this press release, please contact TheProductLawyers.com on 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60010001